Phase II Study of Erlotinib as Third-line Monotherapy in Patients with Advanced Non-small-cell Lung Cancer without Epidermal Growth Factor Receptor Mutations
収録刊行物
-
- Japanese Journal of Clinical Oncology
-
Japanese Journal of Clinical Oncology 41 (8), 959-963, 2011-06-28
Oxford University Press (OUP)